Skip to main content

RCKT

Stock
Health Care
Biotechnology

Performance overview

RCKT Price
Price Chart

Forward-looking statistics

Beta
1.42
Risk
54.38%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Company info

SectorHealth Care
IndustryBiotechnology
Employees236
Market cap$2.1B

Fundamentals

Enterprise value-$28.9M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity6.15

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.63
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$23M
Avg trading volume (10 day)$14M
Put-call ratio—

Macro factor sensitivity

Growth+2.1
Credit+4.3
Liquidity+0.3
Inflation-1.3
Commodities-0.4
Interest Rates-4.1

Valuation

Dividend yield0.00%
PEG Ratio-1.11
Price to sales—
P/E Ratio-1.11
Enterprise Value to Revenue—
Price to book0.75

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

Zacks Investment Research (July 1, 2025)
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability.

Benzinga (May 28, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free